NONMEM Users Network Archive

Hosted by Cognigen

Exciting Opportunity at Eli Lilly and Company for Research Scientist/PK/PD/Pharmacometrics Leader

From: Parag Garhyan <garhyan_parag>
Date: Tue, 24 Jul 2018 21:21:01 +0000

For more than a century, Eli Lilly and Company has united caring with disco=
very to make life better. At Eli Lilly and Company, we continuously focus o=
n new and innovative ways to fulfill our extraordinary purpose of making me=
dicines that help people live longer, healthier, more active lives.

* Are you looking to join a dynamic company striving to improve the=
 lives of people across the world?

* Do you have the passion, curiosity, creativity to dream and the p=
ersistence to get results?

* Do you have the scientific and technical expertise to influence a=
nd apply model-based drug discovery and development?

* Can you communicate effectively with confidence?

If you answered yes then we are looking for you. Eli Lilly and Company is l=
ooking for creative, motivated and enthusiastic scientists to join Global P=
harmacokinetics/Pharmacodynamics and Pharmacometrics department.

The scientists in the department of PK/PD & Pharmacometrics are the team le=
aders in research and development throughout the value chain from preclinic=
al lead molecule identification to clinical post-drug approval with the goa=
l of identifying and developing the right drug with the right dose for the =
right patient and living the model-informed paradigm of drug research and d=
evelopment. Our organization is looking for a dynamic scientist who is able=

* Develop and implement PK/PD approaches and Pharmacometrics strate=
gies to address key questions and influence portfolio decisions, including,=
 but not limited to the application of drug-disease models, literature mode=
ls, quantitative risk/benefit decision tools, quantitative systems pharmaco=
logy models and trial-design optimization analytics.

* Provide scientific leadership in project teams to support the sel=
ection of the right target, molecule, dose, patient population and developm=
ent strategies.

* Expect and understand the issues affecting the drug discovery/dev=
elopment and help derive effective solutions. Support decision-making throu=
gh partnership and collaboration with cross-functional teams and leadership=

* Lead and support the preparation and delivery of overall program =
plan, individual study protocols, analysis plans, data interpretation and s=
tudy reports.

* Assist in the preparation of relevant sections of INDs, IBs, CTDs=
 and other regulatory documents for development and registration of new dru=
gs and line extensions; interact with FDA, EMA, PMDA and other regulatory a=

* Provide coaching and mentoring to fellow scientists within the gr=
oup and in other disciplines as well as interact, teach and collaborate wit=
h academia.

* Represent the group to increase visibility externally, through ke=
y publications, active leadership in key scientific organizations, industry=
 trade groups or consortia.

In summary, in this exciting role you will have opportunities to contribute=
 in developing strategies, setting direction for the organization, and driv=
e successful implementation of the strategies to produce results.

Basic Qualifications:
- PhD and/or MD in relevant scientific field such as biological/ph=
armaceutical sciences, engineering or related field.
- Excellent understanding of clinical pharmacology (PK, PD and pha=
rmacometrics) principles.
- While experience from industry, regulatory, consulting or academ=
ia with exposure to industry is preferred, we are also looking for enthusia=
stic new graduates.

Lilly is an EEO/Affirmative Action Employer and does not discriminate on th=
e basis of age, race, color, religion, gender, sexual orientation, gender i=
dentity, gender expression, national origin, protected veteran status, disa=
bility or any other legally protected status.

If you're interested, please apply at

CONFIDENTIALITY NOTICE: This e-mail message (including all attachments) is =
for the sole use of the intended recipient(s) and may contain confidential =
and privileged information. Any unauthorized review, use, disclosure, copyi=
ng or distribution is strictly prohibited. If you are not the intended reci=
pient, please contact the sender by reply e-mail and destroy all copies of =
the original message.

Received on Tue Jul 24 2018 - 17:21:01 EDT

The NONMEM Users Network is maintained by ICON plc. Requests to subscribe to the network should be sent to:

Once subscribed, you may contribute to the discussion by emailing: